Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis
CA 2488012 A1 · Owner: Clark, Jean Cantwell · Inventors: Clark, Jean Cantwell; Aronow, Bruce Jefferson; Whitsett, Jeffrey Allen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The discovery that CFTR modifier genes in particular the Kir4.2 gene, the , expressed polypeptide(s) as well as genetic and polypeptide regulators thereof, can be used to treat cystic fibrosis (CF) or at least the conditions , that cause CF. Methods and products for detecting and/or identifying CFTR modifier genes, their respective expressed polypeptides the genetic , regulators of such CFTR modifier genes and the regulators of their respective expressed polypeptides are disclosed. Also disclosed are compositions and methods using these CFTR modifier genes their respective expressed , polypeptides genetic regulators of these CFTR modifier genes and/or CFTR , modifier polypeptide …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 30, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 30, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 30, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.